- Revenues hold steady from prior quarter ended June 30,
2021
- Net loss of $100,000, or $(0.04) per share for the second
quarter compared to a net loss of $1.1 million or $(0.52) per share
for the prior quarter ended June 30, 2021
- Break-even EBITDAS for the quarter versus EBITDAS loss of
$800,000 for the prior quarter ended June 30, 2021
- $8.4 million of cash and strengthened balance sheet
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care, nasal care, oral care and dermatological conditions today
announced financial results for its second fiscal quarter and six
months ended September 30, 2021.
“This quarter we focused on our new product launches as well as
strengthening our results of operations and balance sheet,” said
Amy Trombly, CEO of Sonoma Pharmaceuticals. “We are pleased to see
the hard work reflected in improving financial results. Although,
we continue to transition away from unprofitable revenues generated
by an in-house dermatology sales force and our Latin America
partner Invekra, we opened up new, higher margin revenue streams
with our OTC sales, expanded partnerships and new product
introductions. We also raised funds we intend to deploy
commercializing new products and entering new markets.”
Business Highlights for the Second Fiscal Quarter
Sonoma continues to expand the reach of its products through
partners and its own commercialization:
In August, Sonoma launched two new dental products. OroGenix
Oral Hygiene Rinse, developed with its partner Gabriel Science,
LLC, is Sonoma’s second dental product in the U.S. In Switzerland,
Sonoma and its partner, Medical Systems Solutions launched
Microdacyn® Oral Care for both professional and consumer use.
On September 28, 2021, Sonoma launched its OTC products,
Regenacyn® Advanced Scar Gel and Ocucyn® Eyelid & Eyelash
Cleanser, on Amazon.com in the U.S., and MucoClyns™ on Amazon sites
in Europe. All three products are based on Sonoma’s patented
Microcyn® technology and are immediately available for customer
orders.
Also on September 28, 2021, Sonoma launched Regenacyn® Plus, a
prescription-strength scar gel which is available as an
office-dispense product through physician offices.
Together with its partner, Manna Pro, Sonoma now offers three
new indications in animal health specifically for cats. The
MicrocynAH® Cat Opthalmic Gel, MicrocynAH® Cat Eye & Ear Wash,
and MicrocynAH® Cat Wound and Skin Care are now available at
PetSmart.
On October 15, 2021, Sonoma and its partner, the MicroSafe
Group, announced that the Australian Therapeutic Goods
Administration (TGA) approved extended claims for Nanocyn®
Disinfectant and Sanitizer, which is manufactured by Sonoma for its
partner MicroSafe using Sonoma’s patented Microcyn® Technology with
a 15 second kill time against common viruses, including SARS-CoV-2,
Norovirus (Gastro), and influenza, and a 30-second kill contact
time against common bacteria, such as Staphylococcus aureus (MRSA),
E. coli, Pseudomonas aeruginosa, fungi and mold - including Candida
Albicans.
Results for the Second Quarter Ended September 30,
2021
Revenue of $3,744,000 for the second quarter ended September 30,
2021, decreased by $2,025,000, or 35%, from $5,769,000 for the same
period last year. Revenue increased by $60,000, or 2%, from
$3,684,000 for the previous quarter ended June 30, 2021. The
year-over-year decrease was primarily the result of decreases in
revenue in Latin America of $1,506,000 and a decrease of $637,000
in United States revenue from the EMC deal, offset by an increase
in revenue in Europe and the Rest of World of $118,000. The
decrease in revenue in Latin America is the result of the low
margin contract ending with Invekra in October 2020. Since then
Invekra has begun to produce their own product and Sonoma is
manufacturing backup orders at a reduced scale at full cost rather
than reduced prices.
For the quarter ended September 30, 2021, Sonoma reported
revenues of $3,744,000 and cost of revenues of $2,503,000,
resulting in gross profit of $1,241,000 or 33% of revenues,
compared to a gross profit of $2,502,000 or 43% of revenues, for
the same period in the prior year, and compared to a gross profit
of $1,453,000 or 39% of revenues, for the for the June quarter. For
the quarter ended September 30, 2021, gross margins decreased by
10% when compared to the same period last year as a result of the
EMC transition of Sonoma’s dermatological prescription products.
EMC is now managing sales and distribution for those products. As a
result, Sonoma sells products to EMC for a lower cost than it
realized from its own direct sales, however, it also eliminated the
overhead of direct sales.
Total operating expenses during the second quarter of fiscal
year 2021 were $2,205,000, down $128,000, or 5%, when compared to
$2,333,000 during the same period in the prior year. Total
operating expenses were down $152,000, or 6%, when compared to
$2,357,000 during the June quarter. The decrease in total operating
expenses over both periods was primarily related to a reduction in
headcount in direct sales, partially offset by increased insurance
costs.
Net loss from continuing operations for the quarter ended
September 30, 2021, was $(95,000), compared to a net income of
$151,000 for the quarter ended September 30, 2020. EBITDAS income
for the quarter ended September 30, 2021 of $11,000, was down
$354,000, compared to an EBITDAS income of $365,000 for the same
period last year. Net loss from continuing operations for the
quarter ended September 30, 2021, was down $1,003,000, or 91%,
compared to a net loss of $1,098,000 for the quarter ended June 30,
2021. EBITDAS income for the quarter ended September 30, 2021 was
down $808,000, or 101%, compared to an EBITDAS loss of $797,000 for
the previous quarter.
Results for the Six Months Ended September 30, 2021
Revenue of $7,428,000 for the six months ended September 30,
2021, decreased by $4,108,000, or 36%, from $11,536,000 for the
same period last year. This decrease was primarily the result of
decreases in revenue in Latin America of $3,267,000, Europe and
Rest of World of $175,000, and the United States of $666,000,
respectively. The decrease in revenue in Latin America resulted
from the contract termination with Invekra in October 2020. Since
then Invekra has begun to produce their own product and Sonoma is
manufacturing backup orders at a reduced scale at full cost rather
than reduced prices.
For the six months ended September 30, 2021, Sonoma reported
revenues of $7,428,000 and cost of revenues of $4,734,000,
resulting in gross profit of $2,694,000, or 36% of revenues,
compared to a gross profit of $4,757,000 or 41% or revenues. For
the six month ended September 30, 2021, gross margins decreased by
5% when compared to the same periods last year as a result of the
EMC transition of Sonoma’s dermatological prescription products.
EMC is now managing sales and distribution for those products. As a
result, Sonoma sells products to EMC for a lower cost than it
realized from its own direct sales, however it also eliminated the
overhead of direct sales.
Total operating expenses during the six months ended September
30, 2021 of $4,563,000 decreased by $690,000, or 13%, compared to
$5,253,000 during the same period last year. The decrease in total
operating expenses was primarily related to a reduction in
headcount as a result of the EMC deal, partially offset by
increased insurance costs.
Net loss from continuing operations for the six months ended
September 30, 2020, was $(1,193,000), compared to a net loss of
$(557,000) for the same period in prior year. EBITDAS loss for the
six months ended September 30, 2021 of $(979,000), was up $752,000,
compared to an EBITDAS loss of $(227,000) for the same period last
year.
As of September 30, 2021, Sonoma had cash and cash equivalents
of $8,392,000. During the quarter ended September 30, 2021, Sonoma
sold 855,500 shares of common stock through its At The Market
Offering Agreement with HC Wainwright & Co., LLC at average
sales prices of $8.42 per share for gross proceeds of $7,202,000
and net proceeds of $6,902,000 after deducting commissions and
other offering expenses.
Since September 30, 2021, Sonoma sold 94,600 shares of common
stock at an average sales price of $7.39 per share for gross
proceeds of $700,000 and net proceeds of $678,000 after deducting
commissions and other offering expenses.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “reduce,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn®, MicrocynAH®, Microdacyn®,
Regenacyn®, Ocucyn®, MucoClyns™ are trademarks or registered
trademark of Sonoma Pharmaceuticals, Inc. All other trademarks and
service marks are the property of their respective owners.
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
Condensed Consolidated Balance
Sheets
(In thousands, except share and
per share amounts)
(Unaudited)
September 30,
March 31,
2021
2021
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
8,392
$
4,220
Accounts receivable, net
3,416
2,806
Inventories, net
2,482
2,530
Prepaid expenses and other current
assets
3,519
3,218
Current portion of deferred consideration,
net of discount
212
209
Total current assets
18,021
12,983
Operating lease right-of-use assets
700
769
Property and equipment, net
337
360
Deferred consideration, net of discount,
less current portion
694
763
Other assets
76
112
Total assets
$
19,828
$
14,987
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities:
Accounts payable
$
1,876
$
1,769
Accrued expenses and other current
liabilities
987
1,154
Deferred revenue
100
267
Deferred revenue Invekra
53
52
Operating lease liabilities
276
240
Current portion of debt - PPP
587
-
Current portion of long-term debt
199
596
Total current liabilities
4,078
4,078
Operating lease
liabilities-non-current
424
529
Long-term deferred revenue Invekra
205
229
Long-term debt, less current portion -
PPP
-
1,310
Withholding tax payable
3,661
3,478
Total liabilities
8,368
9,624
Commitments and Contingencies
Stockholders’ Equity
Series C Convertible preferred stock,
$0.0001 par value; 714,286 shares authorized at September 30, 2021
and March 31, 2021, 0 shares issued and outstanding at September
30, 2021 and March 31, 2021
–
–
Common stock, $0.0001 par value;
24,000,000 shares authorized at September 30, 2021 and March 31,
2021, 3,004,741 and 2,092,909 shares issued and outstanding at
September 30, 2021 and March 31, 2021, respectively
3
2
Additional paid-in capital
196,438
189,217
Accumulated deficit
(180,475
)
(179,277
)
Accumulated other comprehensive loss
(4,506)
(4,579
)
Total stockholders’ equity
11,460
5,363
Total liabilities and stockholders’
equity
$
19,828
$
14,987
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
Condensed Consolidated
Statements of Comprehensive Loss
(In thousands, except per share
amounts)
(Unaudited)
Three Months Ended
September 30,
Six Months Ended
September 30,
2021
2020
2021
2020
Revenues
$
3,744
$
5,769
$
7,428
$
11,536
Cost of revenues
2,503
3,267
4,734
6,779
Gross profit
1,241
2,502
2,694
4,757
Operating expenses
Research and development
10
(85
)
95
391
Selling, general and administrative
2,195
2,418
4,468
4,862
Total operating expenses
2,205
2,333
4,563
5,253
Income (loss) from operations
(964
)
169
(1,869
)
(496
)
Interest (expense) income, net
(4
)
4
(5
)
4
Other (expense) income, net
723
(77
)
531
(197
)
Gain on sale of assets
150
55
150
132
Income (loss) from continuing
operations
(95
)
151
(1,193
)
(557
)
Income tax expense
(5
)
-
(5
)
-
Income (loss) from discontinued operations
(Note 4)
-
(31
)
-
917
Net income (loss)
$
(100
)
$
120
$
(1,198
)
$
360
Net income (loss) per share: basic
Continuing operations
$
(0.04
)
$
0.08
$
(0.54
)
$
(0.29
)
Discontinued operations
-
(0.02
)
-
0.48
$
(0.04
)
$
0.06
$
(0.54
)
$
0.19
Net income (loss) per share: diluted
Continuing operations
$
(0.04
)
$
0.07
$
(0.54
)
$
(0.26
)
Discontinued operations
-
(0.01
)
-
0.43
$
(0.04
)
$
0.06
$
(0.54
)
$
0.17
Weighted-average number of shares used in
per common share calculations: basic
2,344
2,008
2,219
1,924
Weighted-average number of shares used in
per common share calculations: diluted
2,344
2,159
2,219
2,118
Other comprehensive income (loss)
Net income (loss)
$
(100
)
$
120
$
(1,198
)
$
360
Foreign currency translation
adjustments
(234
)
188
73
355
Comprehensive income (loss)
$
(334
)
$
308
$
(1,125
)
$
715
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
Condensed Consolidated
Statements of Comprehensive Loss
Sequential Comparison
(In thousands, except per share
amounts)
(Unaudited)
Three Months Ended
September 30,
Three Months Ended
June 30,
2021
2020
2021
2020
Revenues
$
3,744
$
5,769
$
3,684
$
5,767
Cost of revenues
2,503
3,267
2,231
3,512
Gross profit
1,241
2,502
1,453
2,255
Operating expenses
Research and development
10
(85
)
84
476
Selling, general and administrative
2,195
2,418
2,273
2,444
Total operating expenses
2,205
2,333
2,357
2,920
Income (loss) from operations
(964
)
169
(904
)
(665
)
Interest (expense) income, net
(4
)
4
(1
)
-
Other (expense) income, net
723
(77
)
(193
)
(121
)
Gain on sale of assets
150
55
-
77
Income (loss) from continuing
operations
(95
)
151
(1,098
)
(709
)
Income tax expense
(5
)
-
-
-
Income (loss) from discontinued operations
(Note 4)
-
(31
)
-
949
Net income (loss)
$
(100
)
$
120
$
(1,098
)
$
240
Net income (loss) per share: basic
Continuing operations
$
(0.04
)
$
0.08
$
(0.52
)
$
(0.39
)
Discontinued operations
-
(0.02
)
-
0.52
$
(0.04
)
$
0.06
$
(0.52
)
$
0.13
Net income (loss) per share: diluted
Continuing operations
$
(0.04
)
$
0.07
$
(0.52
)
$
(0.38
)
Discontinued operations
-
(0.01
)
-
0.51
$
(0.04
)
$
0.06
$
(0.52
)
$
0.13
Weighted-average number of shares used in
per common share calculations: basic
2,344
2,008
2,093
1,839
Weighted-average number of shares used in
per common share calculations: diluted
2,344
2,159
2,093
1,843
Other comprehensive income (loss)
Net income (loss)
$
(100
)
$
120
$
(1,098
)
$
240
Foreign currency translation
adjustments
(234
)
188
307
167
Comprehensive income (loss)
$
(334
)
$
308
$
(791
)
$
407
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
RECONCILIATION OF GAAP
MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
Three Months Ended
September 30,
Six Months Ended
September 30,
2021
2020
2021
2020
(1) Loss from operations minus non-cash
expenses EBITDAS loss:
GAAP income (loss) from continuing
operations as reported
$
(95
)
$
151
$
(1,193
)
$
(557
)
Non-cash adjustments:
Stock-based compensation
55
160
114
223
Depreciation and amortization
51
54
100
107
Non-GAAP income (loss) from operations
minus non-cash expenses EBITDAS income (loss)
$
11
$
365
$
(979
)
$
(227
)
(2) Net loss minus non-cash
expenses:
GAAP net income (loss) as reported
$
(100
)
$
120
$
(1,198
)
$
360
Non-cash adjustments:
Stock-based compensation
55
160
114
223
Depreciation and amortization
51
54
100
107
Non-GAAP net income (loss) minus non-cash
expenses
$
6
$
334
$
(984
)
$
690
(3) Operating expenses minus non-cash
expenses
GAAP operating expenses as reported
$
2,205
$
2,333
$
4,563
$
5,253
Non-cash adjustments:
Stock-based compensation
(55
)
(160
)
(114
)
(223
)
Depreciation and amortization
(51
)
(54
)
(100
)
(107
)
Non-GAAP operating expenses minus non-cash
expenses
$
2,099
$
2,119
$
4,349
$
4,923
(1)
Income (loss) from continuing operations minus non-cash expenses
(EBITDAS) is a non-GAAP financial measure. The company defines
operating income (loss) minus non-cash expenses as GAAP reported
operating income (loss) minus operating depreciation and
amortization, and operating stock-based compensation. The company
uses this measure for the purpose of modifying the operating loss
to reflect direct cash related transactions during the measurement
period.
(2)
Net income (loss) minus non-cash expenses
is a non-GAAP financial measure. The company defines net income
(loss) minus non-cash expenses as GAAP reported net income (loss)
minus depreciation and amortization, stock-based compensation, and
non-cash foreign exchange transaction losses. The company uses this
measure for the purpose of modifying the net loss to reflect only
those expenses to reflect direct cash transactions during the
measurement period.
(3)
Operating expenses minus non-cash expenses
is a non-GAAP financial measure. The company defines operating
expenses minus non-cash expenses as GAAP reported operating
expenses minus operating depreciation and amortization, and
operating stock-based compensation. The company uses this measure
for the purpose of identifying total operating expenses involving
cash transactions during the measurement period.
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
RECONCILIATION OF GAAP
MEASURES TO NON-GAAP MEASURES
SEQUENTIAL COMPARISON
(In thousands)
(Unaudited)
Three Months Ended
September 30,
Three Months Ended
June 30,
2021
2020
2021
2020
(1) Loss from operations minus non-cash
expenses EBITDAS loss:
GAAP income (loss) from continuing
operations as reported
$
(95
)
$
151
$
(904
)
$
(665
)
Non-cash adjustments:
Stock-based compensation
55
160
59
63
Depreciation and amortization
51
54
49
53
Non-GAAP income (loss) from operations
minus non-cash expenses EBITDAS income (loss)
$
11
$
365
$
(797
)
$
(549
)
(2) Net loss minus non-cash
expenses:
GAAP net income (loss) as reported
$
(100
)
$
120
$
(1,098
)
$
240
Non-cash adjustments:
Stock-based compensation
55
160
59
63
Depreciation and amortization
51
54
48
53
Non-GAAP net income (loss) minus non-cash
expenses
$
6
$
334
$
(991
)
$
356
(3) Operating expenses minus non-cash
expenses
GAAP operating expenses as reported
$
2,205
$
2,333
$
2,357
$
2,920
Non-cash adjustments:
Stock-based compensation
(55
)
(160
)
(59
)
(63
)
Depreciation and amortization
(51
)
(54
)
(48
)
(53
)
Non-GAAP operating expenses minus non-cash
expenses
$
2,099
$
2,119
$
2,250
$
2,804
(1)
Income (loss) from continuing operations minus non-cash expenses
(EBITDAS) is a non-GAAP financial measure. The company defines
operating income (loss) minus non-cash expenses as GAAP reported
operating income (loss) minus operating depreciation and
amortization, and operating stock-based compensation. The company
uses this measure for the purpose of modifying the operating loss
to reflect direct cash related transactions during the measurement
period.
(2)
Net income (loss) minus non-cash expenses
is a non-GAAP financial measure. The company defines net income
(loss) minus non-cash expenses as GAAP reported net income (loss)
minus depreciation and amortization, stock-based compensation, and
non-cash foreign exchange transaction losses. The company uses this
measure for the purpose of modifying the net loss to reflect only
those expenses to reflect direct cash transactions during the
measurement period.
(3)
Operating expenses minus non-cash expenses
is a non-GAAP financial measure. The company defines operating
expenses minus non-cash expenses as GAAP reported operating
expenses minus operating depreciation and amortization, and
operating stock-based compensation. The company uses this measure
for the purpose of identifying total operating expenses involving
cash transactions during the measurement period.
SONOMA PHARMACEUTICALS, INC.
AND SUBSIDIARIES
PRODUCT RELATED REVENUE
SCHEDULES
(In thousands)
(Unaudited)
The following table presents the company’s
disaggregated product revenues by geographic region:
Three Months Ended
September 30,
(In thousands)
2021
2020
$ Change
% Change
United States
$
1,347
$
1,984
$
(637
)
(32
%)
Latin America
518
2,024
(1,506
)
(74
%)
Europe and Rest of the World
1,879
1,761
118
7
%
Total
$
3,744
$
5,769
$
(2,025
)
(35
%)
Six Months Ended
September 30,
(In thousands)
2021
2020
$ Change
% Change
United States
$
2,939
$
3,605
$
(666
)
(18
%)
Latin America
1,083
4,350
(3,267
)
(75
%)
Europe and Rest of the World
3,406
3,581
(175
)
(5
%)
Total
$
7,428
$
11,536
$
(4,108
)
(36
%)
Three Months Ended
June 30,
(In thousands)
2021
2020
$ Change
% Change
United States
$
1,592
$
1,620
$
(28
)
(2
%)
Latin America
565
2,327
(1,762
)
(76
%)
Europe and Rest of the World
1,527
1,820
(293
)
(16
%)
Total
$
3,684
$
5,767
$
(2,083
)
(36
%)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211115005455/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024